Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 08, 2022 07:00 ET | Source: First Wave BioPharma, Inc.

First Wave BioPharma to Participate in ”Fireside Chat” at the 34th Annual Roth Conference

BOCA RATON, Fla., March 08, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
February 07, 2022 07:30 ET | Source: First Wave BioPharma, Inc.

First Wave BioPharma to Participate in the 2022 BIO CEO & Investor Conference

BOCA RATON, Fla., Feb. 07, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
January 06, 2022 07:00 ET | Source: First Wave BioPharma, Inc.

First Wave BioPharma Completes Enrollment for Part 2 of RESERVOIR Phase 2 Trial Evaluating FW-COV in COVID-19-Related GI Infections

No Drug-Related SAEs Reported; Topline Data Expected 1H 2022 Part 2 of RESERVOIR Trial to Evaluate Efficacy of FW-COV, an Oral Formulation of Niclosamide, and Expand Safety Observations on...
January 04, 2022 07:00 ET | Source: First Wave BioPharma, Inc.

First Wave BioPharma to Participate in Two Investor Conferences in January 2022

BOCA RATON, Fla., Jan. 04, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
December 13, 2021 07:00 ET | Source: First Wave BioPharma, Inc.

First Wave BioPharma Chairman and CEO Issues Letter to Shareholders

BOCA RATON, Fla., Dec. 13, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
December 09, 2021 07:00 ET | Source: First Wave BioPharma, Inc.

First Wave BioPharma Names Brian Feagan, M.D., to Scientific Advisory Board

BOCA RATON, Fla., Dec. 09, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
December 06, 2021 07:00 ET | Source: First Wave BioPharma, Inc.

First Wave BioPharma’s CEO and President, James Sapirstein, to Participate in CEO Panel Discussion at 2021 BioFlorida Conference

BOCA RATON, Fla., Dec. 06, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
November 30, 2021 07:00 ET | Source: First Wave BioPharma, Inc.

First Wave BioPharma Announces Independent Data Monitoring Committee Provides Positive Interim Safety Assessment for Part 2 COVID-19 RESERVOIR Clinical Trial of Niclosamide for the Treatment of Gastrointestinal Infections

BOCA RATON, Fla., Nov. 30, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
September 14, 2021 07:30 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma

BOCA RATON, Fla., Sept. 14, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
July 22, 2021 16:51 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma Announces $3.0 Million Bought Deal Offering of Common Stock

BOCA RATON, Fla., July 22, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of...

Next Page keyboard_arrow_right